Overview

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Status:
NOT_YET_RECRUITING

Trial end date:
2028-04-17

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

Phase:

PHASE3

Details

Lead Sponsor:

Kailera

Treatments:

semaglutide